Morgan Stanley Trims Sarepta Therapeutics (SRPT) Target Price to $165.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target cut by Morgan Stanley from $169.00 to $165.00 in a research report released on Tuesday, BenzingaRatingsTable reports. They currently have an overweight rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Piper Jaffray Companies increased their price objective on Sarepta Therapeutics from $168.00 to $200.00 and gave the company an overweight rating in a research note on Wednesday, January 30th. Royal Bank of Canada reissued an outperform rating and set a $164.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, January 17th. BidaskClub raised Sarepta Therapeutics from a sell rating to a hold rating in a research note on Thursday, April 25th. Zacks Investment Research raised Sarepta Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 23rd. Finally, Svb Leerink reissued an outperform rating on shares of Sarepta Therapeutics in a research note on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating, twenty-seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $195.90.

Shares of NASDAQ SRPT traded up $0.85 during midday trading on Tuesday, hitting $123.47. 23,081 shares of the company’s stock were exchanged, compared to its average volume of 1,026,596. Sarepta Therapeutics has a 12-month low of $86.55 and a 12-month high of $176.50. The company has a current ratio of 12.17, a quick ratio of 11.15 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $9.09 billion, a price-to-earnings ratio of -22.51 and a beta of 1.98.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative return on equity of 36.26% and a negative net margin of 124.66%. The company had revenue of $87.01 million during the quarter, compared to analyst estimates of $86.92 million. On average, analysts predict that Sarepta Therapeutics will post -4.76 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in SRPT. BNP Paribas Arbitrage SA boosted its position in shares of Sarepta Therapeutics by 3.8% during the first quarter. BNP Paribas Arbitrage SA now owns 2,676 shares of the biotechnology company’s stock valued at $319,000 after buying an additional 98 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its stake in shares of Sarepta Therapeutics by 0.8% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 12,966 shares of the biotechnology company’s stock worth $1,415,000 after acquiring an additional 105 shares in the last quarter. American International Group Inc. boosted its stake in shares of Sarepta Therapeutics by 7.3% during the 4th quarter. American International Group Inc. now owns 1,605 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 109 shares in the last quarter. Cornerstone Advisors Inc. boosted its stake in shares of Sarepta Therapeutics by 71.0% during the 4th quarter. Cornerstone Advisors Inc. now owns 265 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in shares of Sarepta Therapeutics by 4.0% during the 4th quarter. M&T Bank Corp now owns 2,979 shares of the biotechnology company’s stock worth $325,000 after acquiring an additional 114 shares in the last quarter. Institutional investors own 93.01% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: What is the Rule of 72?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.